Study of efgartigimod for new-onset generalized myasthenia gravis
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with generalized myasthenia gravis (gMG) at a moderate to severe stage (classes II, III, or IV).
- You test positive for a specific antibody called AChR-Ab.
- You have not had any prior treatment for gMG except possibly acetylcholine esterase inhibitors (AChEIs).
- Your generalized MG symptoms started within the last 12 months (or eye muscle symptoms within the last 24 months).
- You have a score of 5 or more on the MG-ADL scale, which measures how MG affects your daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
Hear when a new New Onset Generalized Myasthenia Gravis (gMG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.